
Join to View Full Profile
42 William Glen DrCamden, ME 04843
Phone+1 207-470-0445
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Roger Rittmaster, MD is an endocrinologist in Camden, Maine. He is currently licensed to practice medicine in Maine.
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1985
MaineHealthResidency, Internal Medicine, 1977 - 1979
Tufts University School of MedicineClass of 1976
Certifications & Licensure
ME State Medical License 1984 - 2024
ME State Medical License 1984 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 19 citationsEffects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal menWilliam B. White, James S. Bernstein, Roger Rittmaster, Om Dhingra
Journal of Clinical Hypertension. 2021-06-11 - 7 citationsMolecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.Nallasivam Palanisamy, Alexi Tsodikov, Wei Yan, Khalid Suleman, Roger S. Rittmaster
Urologic Oncology. 2015-03-01 - 6 citationsComparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prosta...M. Scott Lucia, David G. Bostwick, Matthew C. Somerville, Ivy L. Fowler, Roger S. Rittmaster
Archives of Pathology & Laboratory Medicine. 2013-11-27
Press Mentions
Testosterone Treament Advances at Raleigh Pharma Startup Led by Former GSK ExecsJanuary 6th, 2021









